Antiplatelet and invasive treatment in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and acute coronary syndrome. The safety of aspirin
Antiplatelet and invasive treatment in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and acute coronary syndrome. The safety of aspirin
复制标题
DOI：
10.1111/jcpt.12262
复制
发表时间：
2015-06-01
影响因子：
2
通讯作者：
Mouzarou, G.
中科院分区：
文献类型：
--
作者：
Kafkas, N. V.;Liakos, C. I.;Mouzarou, G.
研究内容和目的：阿司匹林是治疗急性冠脉综合征（ACS）和经皮冠状动脉介入治疗（PCI）的重要药物。但是，葡萄糖-6-磷酸脱氢酶（G6 PD）缺乏症（溶血性贫血风险）患者禁用。我们报告了2例II级G6 PD缺乏和非ST段抬高ACS患者的治疗病例描述：这两名患者接受了安全有效的双重抗血小板治疗（DAPT，阿司匹林加替格瑞洛）和PCI使用新一代药物洗脱支架（DES），尽管G6 PD缺陷。什么是新的和结论：在II级G6 PD缺陷患者中，使用DAPT和DES进行NSTE-ACS治疗可能是安全有效的。
What is known and objective: Aspirin is an important drug in acute coronary syndromes (ACS) and percutaneous coronary interventions (PCI). However, its use is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency (risk for haemolytic anaemia). We report the management of 2 patients with class II G6PD deficiency and non-ST-segment elevation ACS (NSTE-ACS).Case description: The two patients were safely and efficiently treated with dual antiplatelet treatment (DAPT, aspirin plus ticagrelor) and PCI using new-generation drug-eluting stent (DES) despite G6PD deficiency.What is new and conclusion: NSTE-ACS management with DAPT and DES is probably safe and effective in class II G6PD-deficient patients.